A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs SER 100 (Primary)
  • Indications Isolated systolic hypertension
  • Focus Adverse reactions
  • Sponsors Serodus
  • Most Recent Events

    • 01 Jan 2016 Results analysing safety, tolerability and efficacy published in the Clinical Pharmacology in Drug Development.
    • 09 Sep 2014 Results published in the Media Release.
    • 09 Sep 2014 Status changed from active, no longer recruiting to completed, as reported in a Serodus media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top